Tue 2/28/2017 02:52 ET
DJIA20837.4415.680.08%SOLAR19.100.140.74%GOLD1253.205.140.41%Shanghai3136.7734.501.10%
S&P 5002369.732.370.10%BANKS24.550.130.53%OIL54.070.080.15%Nikkei19118.9911.470.06%
NASDAQ5861.9016.410.28%SEMI77.100.370.48%US/EU1.060.000.34%Futures2367.500.750.03%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Stocks For A Different Jungle (ACADIA Pharmaceuticals - ACAD)    If it belongs at the Pit it doesn't belong here.

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ACAD
  
From: singhtelecom (Rep: 953)Date: 02/19/2017 04:07
Forum: Stocks For A Different Jungle - Msg #19100 - List ACAD msgs Thread #673907886 (Rec: 0)
Baker Brothers Advisors owns about 25.8 million shares or 21% of the company. Additionally, Fidelity owns 18.1 million shares or 15% of the company. There are currently 94 million shares in the float, and nearly 37% of those are tied up between those two holders.

Baker Brothers' stake goes beyond owning shares. Dr. Stephen Biggar is the chairman of ACAD's board and a partner at Baker Brothers. Meanwhile, Julian Baker—a managing partner at Baker Brothers—is also on the ACAD board of directors. There are reports that many of the board members have had relationships with Baker Brothers in the past. In March 2016, there was a board and management turnover, and as a result, the firm began asserting influence over the new team. The turnover occurred after the previous CEO resigned due to delays in filings needed to get Nuplazid in front of the FDA. There are currently only seven members on the board.

Stephen Davis is the chief executive officer of ACAD and is on board. He was an executive vice president and COO at Heron Therapeutics (HRTX​). SEC filings show the Baker Brothers own about a 10% stake in Heron Therapeutics. He was also the CEO of Neurogen, while Julian Baker was on the Board of Neurogen, at the time. Jim Daly is on the board and had been an Executive Vice President and Chief Commercial Officer at Incyte Corp. (INCY​). Bakers owns about 12.2% of INCY. Edmund Harrigan has roots back to Neurogen as well, when Stephen Davis was CEO and Julian Baker was on the board. All this shows the commitment Baker Brothers has made to see through the successful development of Nuplazid.



Read more: A Look at the Big Gains in Acadia Pharmaceuticals in 2017 (ACAD) | Investopedia http://www.investopedia.com/articles/investing/021617/look-big-gains-acadia-pharmaceuticals-2017-acad.asp#ixzz4Z7WXr94E
Follow us: Investopedia on Facebook

Share This Post:


What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreACAD: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add ACAD
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.